Gravity Analytica

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

ASND 11.07.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-14

Name of Upcoming Event:Conference Call and Live Webcast

Full Press Release SEC Filings Our ASND Tweets

About Gravity Analytica

Recent Filings

PDF Version

COPENHAGEN, Denmark,Nov. 07, 2024(GLOBE NEWSWIRE) --Ascendis Pharma A/S(Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update onThursday, November 14, 2024, after the close of theU.S.financial markets.Ascendis Pharmawill also host a conference call and live webcast onNovember 14, 2024, at4:30 p.m. Eastern Time(ET) to discuss its third quarter 2024 financial results.

Those who would like to participate may access the live webcasthere, or register in advance for the teleconferencehere. The link to the live webcast will also be available on the Investors & News section of theAscendis Pharmawebsite athttps://investors.ascendispharma.com. A replay of the webcast will be available on this section of theAscendis Pharmawebsite shortly after conclusion of the event for 30 days.

AboutAscendis Pharma A/SAscendis Pharmais applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered inCopenhagen, Denmarkand has additional facilities inEuropeandthe United States. Please visitascendispharma.comto learn more.

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with theU.S. Securities and Exchange Commission(SEC) onFebruary 7, 2024, and Ascendis’ other future reports filed with, or submitted to, theSEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group. ©November 2024Ascendis Pharma A/S.

Investor Contacts:		Media Contact:
Scott Smith		Melinda Baker
Ascendis Pharma		Ascendis Pharma
ir@ascendispharma.com		+1 (650) 709-8875
		media@ascendispharma.com

Patti Bank
ICR Healthcare
+1 (415) 513-1284
patti.bank@westwicke.com

Source: Ascendis Pharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com